Kite Pharma
Santa Monica
California
United States
316 articles about Kite Pharma
-
The new FDA-approved manufacturing process for Kite’s CAR-T cell therapy Yescarta will allow a 14-day turnaround compared to 16 days, the company announced on Tuesday.
-
Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy
1/30/2024
Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta ® CAR T-cell Therapy.
-
New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers
12/12/2023
Kite, a Gilead Company, announced the results of four new analyses supporting the use of Tecartus® in relapsed/refractory mantle cell lymphoma and relapsed/refractory adult B-cell precursor acute lymphoblastic leukemia.
-
Analyses of Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas
12/12/2023
Kite, a Gilead Company, announced data from follow-up analyses of three studies of Yescarta® that demonstrate the long-term survival potential for patients living with several sub-types of relapsed or refractory non-Hodgkin lymphoma, which were presented at the 65th American Society of Hematology Annual Meeting & Exposition.
-
ASH 23: CAR-T for Autoimmune, Arcellx's Multiple Myeloma Challenger and Seagen's Combo Play
12/11/2023
A CAR-T cell therapy for autoimmune diseases generated significant attention at the 2023 American Society of Hematology (ASH) annual meeting and Arcellx and Seagen posted promising data. -
The market size for biologic oncology therapies will reach $786 billion by 2029, far outstripping small molecules, a GlobalData report predicts.
-
Kite and Arcellx Announce Expansion in Strategic Partnership
11/15/2023
Kite, a Gilead Company, and Arcellx, Inc., announced that the companies have expanded their existing collaboration, which was originally announced in December 2022.
-
Arcellx and Kite Announce Expansion in Strategic Partnership
11/15/2023
Arcellx, Inc. and Kite, a Gilead Company, announced that the companies have expanded their existing collaboration, which was originally announced in December 2022.
-
Months after the FDA lifted its partial hold on their Phase II multiple myeloma program, Kite and Arcellx are expanding their existing development and commercialization collaboration in the blood cancer space.
-
Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023
11/2/2023
Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023.
-
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
9/18/2023
Kite, a Gilead Company, announced results from the Phase 2 ALYCANTE study, led and sponsored by the French collaborative group LYSA/LYSARC, for use of its chimeric antigen receptor T-cell therapy Yescarta® in patients with relapsed/refractory large B-cell lymphoma after one prior line of therapy who were deemed ineligible for high-dose chemotherapy and autologous stem cell transplantation.
-
The study participant who died was apparently ineligible for the treatment according to the trial protocol, Arcellx announced Monday. The company has since retrained the study’s clinical sites.
-
The company announced Monday with its second-quarter earnings that the regulator has officially halted the Phase I study after a child with acute myeloid leukemia died following treatment.
-
Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan
6/22/2023
Kite Announces Completion of Marketing Authorization Transfer for Yescarta ® CAR T-cell Therapy in Japan.
-
Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
6/1/2023
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 17 abstracts from its industry-leading cell therapy portfolio and growing blood cancer pipeline at the upcoming 2023 European Hematology Association (EHA).
-
Yescarta is the first treatment in nearly 30 years to improve overall survival in relapsed/refractory large B-cell lymphoma R/R LBCL, according to Gilead's Kite Pharma.
-
Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
3/21/2023
Kite, a Gilead Company (Nasdaq: GILD), today announced the primary overall survival (OS) analysis results of the Phase 3 ZUMA-7 study.
-
Kite Completes Acquisition of Tmunity
2/22/2023
Kite, a Gilead Company (NASDAQ: GILD), today announced the completion of the previously announced transaction to acquire Tmunity Therapeutics (Tmunity), a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.
-
Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
2/9/2023
Kite’s Tecartus ® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
-
Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma
12/22/2022
Kite Pharma, Inc., a Gilead Company, (hereafter, Kite) (NASDAQ: GILD) and Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) (TSE: 4568) today jointly announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has approved Yescarta (axicabtagene ciloleucel).